Skip to Main Content
Pharmacist's Letter
Menu
    • Products
      • Hospital Pharmacist's Letter
      • Hospital Pharmacy Technician's Letter
      • Learning Management Portal
      • Natural Medicines
      • Pharmacist's Letter
      • Pharmacist's Letter Canada
      • Pharmacy Technician's Letter
      • Pharmacy Technician's Letter Canada
      • Prescriber's Letter
      • RxAdvanced
      • RxSelect

    Subscribe Login
  • Home
  • Letter
    • Current Issue
    • Past Issues
    • Suggest a Topic
  • Browse
    • Subject
    • Charts
    • COVID-19 Resources
    • Diabetes Resources
    • Immunization Resources
    • Natural Medicines Resources
    • Opioid Resources
    • Transitions of Care Resources
    • Journal Club
  • CE & Training
    • CE Organizer
    • Available Courses
    • Live CE Calendar
    • Print Statements
    • Licenses
    • NABP
    • Additional Requirements
    • Exemptions
  • Podcasts
  • New Drugs
    • New Drugs
    • First Time Generics
  • Help
    • User Support
    • Contact Us

Upgrade Your Browser

We no longer support this version of your browser. We recommend that you upgrade to the latest version of Internet Explorer, Firefox, Chrome or Safari to improve your security and experience using this website.

Return to the course you were viewing

  1. Home
  2. Browse
  3. Diabetes & Endocrinology
  4. Resources

Resources

  • Diabetes (712)
  • Endocrinology (8)
  • Hyperglycemia (31)
  • Hypoglycemia (15)
  • Other (31)
  • Prediabetes (5)
  • Resources (272)
    • Charts (55)
    • Guidelines (81)
    • Letters (3)
    • Natural Medicines / Supplements (4)
    • Patient Education (12)
    • PL Voices (153)
    • Quality Measures (39)
  • Thyroid Disorders (53)
196 - 210 of 272 Results
Sort Results:
  • Title: Ascending (A-Z)
  • Date: Newest First
  • Date: Oldest First
Commentary: Actos (Pioglitazone) and Risk of Bladder Cancer October 2010
Chart: Stepwise Approach to Selecting Treatments for Type 2 Diabetes (AACE) October 2010
Other: See new FDA information concerning the restricted use of Avandia August 2010
Guideline: Consensus Statement on Management of Hyperglycemia in Type 2 Diabetes (ADA, 2009) August 2010
Patient Education: Avandia and Risk of Heart Attack August 2010
Article: Many supplements are promoted for diabetes August 2010
Guideline: Aspirin for Primary Prevention of Cardiovascular Events in People with Diabetes (2010) July 2010
Commentary: Aspirin for Primary Prevention in Patients with Diabetes July 2010
Guideline: Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach (2012) May 2010
Guideline: AACE Diabetes Management Consensus Statement (2013). May 2010
Commentary: Avandia and Cardiovascular Safety: Ongoing Review April 2010
Other: Senate Concerns about Avandia April 2010
Commentary: Insulins March 2010
Commentary: New Drug: Victoza (Liraglutide) March 2010
Guideline: ADA Standards of Medical Care in Diabetes February 2010
  • « Prev
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • Next »
  • About Us
  • Our Mission
  • Our Team
  • Careers
  • News and Resources
  • Products
  • Individual Solutions
  • Enterprise Solutions
  • Support & Policies
  • Contact Us
  • Access Agreement
  • Privacy Policy

The contents of this website are not intended to be a substitute for professional medical advice, diagnosis, or treatment. See additional information.

© Therapeutic Research Center. All Rights Reserved